Phase I: Relapsed or Refractory B-cell Malignancies
Oncology·MeSH: Lymphoma, Mantle-Cell
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| Acalabrutinib | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Phase I: Relapsed or Refractory B-cell Malignancies?
BioSniper tracks 1 drug in development for Phase I: Relapsed or Refractory B-cell Malignancies across 1 company.
How many clinical trials target Phase I: Relapsed or Refractory B-cell Malignancies?
There are 1 clinical trial targeting Phase I: Relapsed or Refractory B-cell Malignancies tracked by BioSniper.
Deep-dive into Phase I: Relapsed or Refractory B-cell Malignancies
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis